Newsroom

SOUTH SAN FRANCISCO, Calif. – December 3, 2024 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the recent initiation of dosing in a Phase 1 clinical trial of NEU-111 in healthy volunteers. NEU-111 is a potent and highly selective oral allosteric inhibitor […]

NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease Global Phase 2 clinical trial leverages Roche-developed digital biomarker as primary endpoint for enhanced precision and efficiency over traditional clinical rating scales Collaborations with QIAGEN, Sano Genetics and Quest Diagnostics to […]

Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease SOUTH SAN FRANCISCO, Calif., November 19, 2024 – Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced a collaboration with Roche to […]

Senior industry leader brings substantial strategy, business development, and operations experience SOUTH SAN FRANCISCO, Calif. – August 22, 2023 – Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO). Mr. Yost […]

NEU-723 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor First-of-its-kind companion diagnostic paired with NEU-723 will enable selection of patients likely to respond to therapy SOUTH SAN FRANCISCO, Calif. – February 7, 2023 – Neuron23™ Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]

Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN’s long-standing experience in companion diagnostic development SOUTH SAN FRANCISCO, Calif. and GERMANTOWN, Md. and HILDEN, Germany, Sept. 14, 2022 /PRNewswire/ — Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]

Longtime clinical development leader will help advance pipeline of precision medicines for genetically defined neurological and immunological diseases, with initial focus on Parkinson’s disease SOUTH SAN FRANCISCO, Calif., April 12, 2022 – Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment […]

SoftBank Vision Fund 2 leads round with participation from all existing investors . Company expects to bring LRRK2 candidate into the clinic for Parkinson’s disease by end of 2022. Valentin Barsan, M.D., and Jim Scopa join Neuron23 board of directors

Biotechnology company launches to accelerate development of precision medicines for genetically defined neurological and immunological diseases